AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Monopar Therapeutics Director's Dealing 2025

Mar 7, 2025

32883_dirs_2025-03-06_fa8f54b6-6e0d-4d4b-a2bc-a92359950a36.zip

Director's Dealing

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2025-02-21

Reporting Person: Talukdar Lavina (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	14001	Direct